{
    "title": "112_hr4332",
    "content": "The Act titled \"Generic Drug Application Review Fairness Act of 2012\" extends the period for the first applicant to obtain tentative approval without forfeiting the 180-day exclusivity period. The Act extends the period for the first applicant to obtain tentative approval under certain conditions. The Act extends the period for the first applicant to obtain tentative approval under certain conditions, with the amendment applying to applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act on or after 30 months. The Act extends the period for the first applicant to obtain tentative approval under certain conditions for applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The Act extends the period for the first applicant to obtain tentative approval under certain conditions for applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Effective October 1, 2013, the duration is reduced from 60 months to 54 months, then to 48 months on October 1, 2014, and further reduced on October 1, 2015. Effective on October 1, 2015, the duration for the first applicant to obtain tentative approval under certain conditions is reduced from 48 months to 42 months. On October 1, 2016, it is further reduced to 36 months, and on October 1, 2017, it is reduced again. The duration for tentative approval is reduced from 36 months to 30 months for applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The amendments apply to applications filed or amended within one fiscal year of the effective date. The amendment reduces the tentative approval duration to 30 months for applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. It applies to applications filed or amended after October 1, 2017. A conforming amendment is made to section 505(q)(1) of the Act. The amendment establishes the Office of Generic Drugs within the Center for Drug Evaluation and Research of the FDA. The Director of the Office of Generic Drugs will report directly to the Director of the Center for Drug Evaluation and Research."
}